Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Bacillus Calmette-Guérin Stories

2012-08-09 10:28:55

Treatment with generic vaccine kills autoimmune cells, temporarily restoring insulin production A phase I clinical trial has confirmed that use of a generic vaccine to raise levels of an immune system modulator can cause the death of autoimmune cells targeting the insulin-secreting cells of the pancreas and temporarily restore insulin secretion in human patients with type 1 diabetes. Results of the study — led by Denise Faustman, MD, PhD, director of the Massachusetts General...

2012-07-11 10:23:18

OTTAWA, July 11, 2012 /CNW/ - Health Canada has completed a thorough health risk assessment of the bladder cancer treatment ImmuCyst produced at Sanofi Pasteur's manufacturing plant in Toronto. A Health Canada inspection of Building 86 at Sanofi Pasteur's manufacturing plant in Toronto found the presence of mould in the sterile manufacturing areas where ImmuCyst was produced. Health Canada's review has concluded that ImmuCyst should remain available to bladder cancer patients,...

2012-06-15 10:23:07

OTTAWA, June 15, 2012 /CNW/ - Health Canada is advising Canadians that Sanofi Pasteur is voluntarily recalling all Bacille Calmette-Guérin (BCG) vaccine on the market because of problems in the manufacturing facility that Health Canada believes may have affected the vaccine quality. BCG is used to prevent serious complications of tuberculosis (TB) infection, notably for infants and children living in First Nation and Inuit communities at high risk for tuberculosis...

2012-06-05 18:22:44

BOSTON, June 6, 2012 /PRNewswire/ -- The U.S. faces major obstacles in taking advantage of "value-based health care"--one of the most promising developments in health care, according to a new study by The Boston Consulting Group (BCG). (Photo: http://photos.prnewswire.com/prnh/20120606/NY19587 ) BCG assessed the progress of 12 developed-world countries in adopting value-based health care, an approach to better controlling health care costs by improving health outcomes at the same or lower...

2012-05-31 06:28:19

BRONX, N.Y., May 31, 2012 /PRNewswire-USNewswire/ -- The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium...

2012-05-22 02:32:17

The tuberculosis vaccine is often used as a treatment for bladder cancer, and adding vitamin D might improve the vaccine´s effectiveness, according to new research from the University of Rochester Medical Center presented today at the American Urological Association annual meeting. Yi-Fen Lee, Ph.D., associate professor of Urology at URMC, has conducted a pre-clinical study in a mouse model showing that a combination of vitamin D therapy and the Bacillus Calmette-Guerin (BCG) vaccine...

2012-05-09 06:26:18

First Phase I study of vaccine candidate planned for this year ROCKVILLE, Md. and SEATTLE, May 9, 2012 /PRNewswire-USNewswire/ -- Aeras and the Infectious Disease Research Institute (IDRI) announce today a new agreement to conduct joint development activities with respect to IDRI's novel tuberculosis vaccine candidate. This collaboration reflects the missions of the two non-profit product development partnerships to use cutting-edge science to develop products that address critical...

2012-03-21 05:45:41

(Ivanhoe Newswire) — New, more effective vaccines will be decisive in the fight against TB. More than 10 million children have been orphaned by the disease, which is rapidly becoming resistant to available treatment options. Top scientific experts, all over the world, are working together to develop a vaccine that will eliminate TB on all fronts and levels. To address the many challenges posed by TB, ideal vaccine regimens must protect babies at birth from childhood TB, and prevent...

2012-03-20 06:26:16

NEW YORK, March 20, 2012 /PRNewswire/ -- The medical industry and The Bull Consulting Group (BCG) have a successful history together. Over the past 3 years, three public medical companies selected BCG to provide financing, investor relations, and promotional services. Starting in 2009, a small public company entered into agreement with BCG to provide financing and liquidity with its public market. BCG, through organization of institutional buying, and through collateral based debt...

2012-03-20 11:25:48

In the past decade, scientists have made significant progress building the critical knowledge and infrastructure needed to identify and develop novel tuberculosis (TB) vaccine candidates and move the most promising ones into human clinical trials. The results of those trials, coupled with advances from other TB studies, have paved the way for the next 10 years of research on TB vaccines, a critical component of TB control efforts, note scientists at the National Institute of Allergy and...


Latest Bacillus Calmette-Guérin Reference Libraries

45_255d6ba67dfe6f32b9c7c31f338bf912
2011-04-18 22:11:24

Mycobacterium bovis is a slow-growing, aerobic bacterium and the causative agent of tuberculosis in cattle. Similar to M. tuberculosis, M. bovis can jump the species barrier and cause tuberculosis in humans. It is estimated that M. bovis was responsible for more losses among farm animals than all other diseases combined in the first half of the 20th century. Infection happens after bacterium is ingested. It is generally transmitted to humans via infected milk. Actual human infections are...

More Articles (1 articles) »